{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:04Z","timestamp":1792269544794,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,16]]},"DOI":"10.7759\/cureus.114593","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T10:33:57Z","timestamp":1786876437000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Disseminated Encephalomyelitis Following Nivolumab Therapy for Hodgkin Lymphoma: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Amal","family":"Abudouleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Sondoqah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areen","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell SM","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al.. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015, 372:311-9. 10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, et al.. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019, 7:134. 10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2019.1417","article-title":"Nivolumab-associated acute demyelinating encephalitis: a case report and literature review","volume":"17","author":"Zafar Z","year":"2019","unstructured":"Zafar Z, Vogler C, Hudali T, Bhattarai M. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin Med Res. 2019, 17:29-33. 10.3121\/cmr.2019.1417","journal-title":"Clin Med Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/children7110210","article-title":"Acute disseminated encephalomyelitis: current perspectives","volume":"7","author":"Paolilo RB","year":"2020","unstructured":"Paolilo RB, Deiva K, Neuteboom R, Rost\u00e1sy K, Lim M. Acute disseminated encephalomyelitis: current perspectives. Children (Basel). 2020, 7:210. 10.3390\/children7110210","journal-title":"Children (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera AF","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, et al.. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. N Engl J Med. 2024, 391:1379-89. 10.1056\/NEJMoa2405888","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei SC","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018, 8:1069-86. 10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666201230151224","article-title":"Immune checkpoint inhibitors and neurotoxicity","volume":"19","author":"Zhao Z","year":"2021","unstructured":"Zhao Z, Zhang C, Zhou L, Dong P, Shi L. Immune checkpoint inhibitors and neurotoxicity. Curr Neuropharmacol. 2021, 19:1246-63. 10.2174\/1570159X19666201230151224","journal-title":"Curr Neuropharmacol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp LB","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP, et al.. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013, 19:1261-7.","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira MC","year":"2020","unstructured":"Oliveira MC, de Brito MH, Simabukuro MM. Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature. Front Neurol. 2020, 11:538695. 10.3389\/fneur.2020.538695","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-66. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus F","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al.. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016, 15:391-404. 10.1016\/S1474-4422(15)00401-9","journal-title":"Lancet Neurol"},{"key":"ref16","article-title":"Autoimmune encephalitis related to nivolumab followed by tumor regression","volume":"83","author":"Mysler SJ","year":"2023","unstructured":"Mysler SJ, Perazzo F, Mand\u00f3 P. Autoimmune encephalitis related to nivolumab followed by tumor regression. Medicina (B Aires). 2023, 83:479-83.","journal-title":"Medicina (B Aires)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2022.71","article-title":"Nivolumab-induced limbic encephalitis associated with glutamic acid decarboxylase 65 antibodies","volume":"50","author":"AlSabah AA","year":"2023","unstructured":"AlSabah AA, Altman R. Nivolumab-induced limbic encephalitis associated with glutamic acid decarboxylase 65 antibodies. Can J Neurol Sci. 2023, 50:635-6. 10.1017\/cjn.2022.71","journal-title":"Can J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.07.005","article-title":"Encephalitis in non-small-cell lung cancer","volume":"27","author":"Costa e Silva M","year":"2021","unstructured":"Costa e Silva M, Silva E, Mendes A, Barroso A. Encephalitis in non-small-cell lung cancer. Pulmonology. 2021, 27:582-3. 10.1016\/j.pulmoe.2021.07.005","journal-title":"Pulmonology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.04.177","article-title":"Case report of immuno-oncotherapy (IO) provoked encephalitis mimicking brain metastasis in a patient with history of traumatic brain injury","volume":"139","author":"Bross SP","year":"2020","unstructured":"Bross SP, Mongelluzzo GJ, Conger AR, Patel MA, Vadakara J, Grant M, Gatson NT. Case report of immuno-oncotherapy (IO) provoked encephalitis mimicking brain metastasis in a patient with history of traumatic brain injury. World Neurosurg. 2020, 139:483-7. 10.1016\/j.wneu.2020.04.177","journal-title":"World Neurosurg"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1177\/0300891620951262","article-title":"Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report","volume":"106","author":"Guidi A","year":"2020","unstructured":"Guidi A, Violati M, Blasi M, Ferrari E, Luciani A, Codec\u00e0 C, Ferrari D. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report. Tumori. 2020, 106:NP23-8.","journal-title":"Tumori"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1725508","article-title":"Nivolumab-induced autoantibody negative limbic encephalitis in a patient with Hodgkin lymphoma","volume":"61","author":"Erol-Y\u0131ld\u0131z R","year":"2020","unstructured":"Erol-Y\u0131ld\u0131z R, K\u0131z\u0131lay T, T\u00fcz\u00fcn E, M\u0131s\u0131rl\u0131 H, T\u00fcrko\u011flu R. Nivolumab-induced autoantibody negative limbic encephalitis in a patient with Hodgkin lymphoma. Leuk Lymphoma. 2020, 61:1519-21. 10.1080\/10428194.2020.1725508","journal-title":"Leuk Lymphoma"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1177\/1078155220904147","article-title":"Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: a case report","volume":"26","author":"Taillefer VT","year":"2020","unstructured":"Taillefer VT, Pigeon M, Chen M, Larochelle C, Florescu M, B\u00e9langer K, Adam JP. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: a case report. J Oncol Pharm Pract. 2020, 26:1538-43.","journal-title":"J Oncol Pharm Pract"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577350","article-title":"Nivolumab-induced seronegative encephalitis","volume":"347","author":"Cabral G","year":"2020","unstructured":"Cabral G, Ladeira F, Gil N. Nivolumab-induced seronegative encephalitis. J Neuroimmunol. 2020, 347:577350. 10.1016\/j.jneuroim.2020.577350","journal-title":"J Neuroimmunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.29399\/npa.23353","article-title":"Autoimmune encephalitis after treatment of Hodgkin's lymphoma with the immune checkpoint inhibitor nivolumab","volume":"58","author":"Nalbanto\u011flu M","year":"2021","unstructured":"Nalbanto\u011flu M, Altunrende B, Tun\u00e7er \u00d6G, Akman G. Autoimmune encephalitis after treatment of Hodgkin's lymphoma with the immune checkpoint inhibitor nivolumab. Noro Psikiyatr Ars. 2021, 58:163-5. 10.29399\/npa.23353","journal-title":"Noro Psikiyatr Ars"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.03.007","article-title":"A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer","volume":"24","author":"Burke M","year":"2018","unstructured":"Burke M, Hardesty M, Downs W. A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer. Gynecol Oncol Rep. 2018, 24:51-3. 10.1016\/j.gore.2018.03.007","journal-title":"Gynecol Oncol Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4273231","article-title":"Nivolumab-induced encephalitis in hereditary leiomyomatosis and renal cell cancer syndrome","volume":"2018","author":"Chaucer B","year":"2018","unstructured":"Chaucer B, Stone A, Demanes A, Seibert SM. Nivolumab-induced encephalitis in hereditary leiomyomatosis and renal cell cancer syndrome. Case Rep Oncol Med. 2018, 2018:4273231. 10.1155\/2018\/4273231","journal-title":"Case Rep Oncol Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2548528","article-title":"Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma","volume":"2018","author":"Shah S","year":"2018","unstructured":"Shah S, Dunn-Pirio A, Luedke M, Morgenlander J, Skeen M, Eckstein C. Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med. 2018, 2018:2548528. 10.1155\/2018\/2548528","journal-title":"Case Rep Neurol Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0363-6","article-title":"Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease","volume":"54","author":"De la Hoz A","year":"2019","unstructured":"De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP. Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. Bone Marrow Transplant. 2019, 54:749-51. 10.1038\/s41409-018-0363-6","journal-title":"Bone Marrow Transplant"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.009","article-title":"Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung","volume":"19","author":"Matsuoka H","year":"2018","unstructured":"Matsuoka H, Kimura H, Koba H, et al.. Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer. 2018, 19:e597-9. 10.1016\/j.cllc.2018.04.009","journal-title":"Clin Lung Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report","volume":"12","author":"Kopeck\u00fd J","year":"2018","unstructured":"Kopeck\u00fd J, Kube\u010dek O, Geryk T, Slov\u00e1\u010dkov\u00e1 B, Hoffmann P, \u017diaran M, Priester P. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep. 2018, 12:262. 10.1186\/s13256-018-1786-9","journal-title":"J Med Case Rep"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729069","article-title":"A case report of steroid responsive nivolumab-induced encephalitis","volume":"24","author":"Richard K","year":"2017","unstructured":"Richard K, Weslow J, Porcella SL, Nanjappa S. A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control. 2017, 24:1073274817729069.","journal-title":"Cancer Control"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1159\/000477162","article-title":"PD-1 checkpoint inhibitor associated autoimmune encephalitis","volume":"10","author":"Schneider S","year":"2017","unstructured":"Schneider S, Potthast S, Komminoth P, Schwegler G, B\u00f6hm S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017, 10:473-8. 10.1159\/000477162","journal-title":"Case Rep Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin J","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al.. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017, 22:709-18. 10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/518322-acute-disseminated-encephalomyelitis-following-nivolumab-therapy-for-hodgkin-lymphoma-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T10:33:58Z","timestamp":1786876438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/518322-acute-disseminated-encephalomyelitis-following-nivolumab-therapy-for-hodgkin-lymphoma-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.114593","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}